CGEM Stock Overview
Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Cullinan Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$15.66 |
| 52 Week High | US$20.62 |
| 52 Week Low | US$7.64 |
| Beta | 0.33 |
| 1 Month Change | 0.84% |
| 3 Month Change | 36.06% |
| 1 Year Change | 45.13% |
| 3 Year Change | -50.27% |
| 5 Year Change | n/a |
| Change since IPO | -47.64% |
Recent News & Updates
Recent updates
Cullinan Oncology: Modality-Agnostic Approach To Yield Fruit In Coming Years
Sep 22Cullinan Oncology: One Of The Leaders In Cancer Treatment Development
Sep 14Cullinan Oncology grants stock options for 125.7K shares
Sep 02Companies Like Cullinan Oncology (NASDAQ:CGEM) Are In A Position To Invest In Growth
Jun 24
Here's Why We're Not Too Worried About Cullinan Oncology's (NASDAQ:CGEM) Cash Burn Situation
Mar 05Companies Like Cullinan Oncology (NASDAQ:CGEM) Are In A Position To Invest In Growth
Oct 08Cullinan Oncology: Hub-And-Spoke Business Model For Drug Development
Jun 30Cullinan Oncology (CGEM) Presents At 2021 ASCO Annual Virtual Meeting - Slideshow
Jun 05Cullinan initiated Buy at H.C. Wainwright on pipeline strength
Feb 02Shareholder Returns
| CGEM | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -6.1% | -4.7% | -3.7% |
| 1Y | 45.1% | -2.7% | 20.2% |
Return vs Industry: CGEM exceeded the US Biotechs industry which returned -2.7% over the past year.
Return vs Market: CGEM exceeded the US Market which returned 20.2% over the past year.
Price Volatility
| CGEM volatility | |
|---|---|
| CGEM Average Weekly Movement | 8.8% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CGEM's share price has been volatile over the past 3 months.
Volatility Over Time: CGEM's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 85 | Nadim Ahmed | cullinantherapeutics.com |
Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company’s lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.
Cullinan Therapeutics, Inc. Fundamentals Summary
| CGEM fundamental statistics | |
|---|---|
| Market cap | US$777.77m |
| Earnings (TTM) | -US$153.16m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.4x
P/E RatioIs CGEM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CGEM income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$153.16m |
| Earnings | -US$153.16m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.56 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CGEM perform over the long term?
See historical performance and comparison